Inferra AI / Company / BIO
Bio-Rad Laboratories, Inc.
BIO · Industrials
Last earnings Aug 4, 2026
Key results
Revenuequarter
$ 651.6
Financial Results Highlights GAAP Results Q2 2025 Q2 2024 Revenue (millions) $ 651.6 $ 638.5 Gross margin 53.0 % 55.6 % Income from operations $ 77.1 $ 101.5 Net income (loss) (millions) $ 317.8 $ (2,165.5) Income (loss) per diluted share $ 11.67 $ (76.26) Non-GAAP Results Q2 2025 Q2 2024 Revenue (millions) $ 651.6 $ 638.5 Gross margin 53.7 % 56.4 % Income from operations $ 88.6 $ 106.9 Net income (millions) $ 71.0 $ 88.3 Income per diluted share $ 2.61 $ 3.11 The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading Use of Non-GAAP and Currency-Neutral Reporting.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Gross marginquarter
53.0 %
Financial Results Highlights GAAP Results Q2 2025 Q2 2024 Revenue (millions) $ 651.6 $ 638.5 Gross margin 53.0 % 55.6 % Income from operations $ 77.1 $ 101.5 Net income (loss) (millions) $ 317.8 $ (2,165.5) Income (loss) per diluted share $ 11.67 $ (76.26) Non-GAAP Results Q2 2025 Q2 2024 Revenue (millions) $ 651.6 $ 638.5 Gross margin 53.7 % 56.4 % Income from operations $ 88.6 $ 106.9 Net income (millions) $ 71.0 $ 88.3 Income per diluted share $ 2.61 $ 3.11 The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading Use of Non-GAAP and Currency-Neutral Reporting.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Life Science segment net sales for the second quarter were $262.8 million, an increase of 4.9 percent compared to the same period in 2024.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
On a currency-neutral basis, Life Science segment sales increased by 3.8 percent compared 1 to the same quarter in 2024.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Clinical Diagnostics segment net sales for the second quarter were $388.8 million, essentially flat compared to the same period in 2024.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Net incomequarter
$317.8 million
net income of $317.8 million, or $11.67 per share, on a diluted basis, versus a net loss of $(2,165.5) million, or $(76.26) per share, on a diluted basis, reported for the same period of 2024.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Non-GAAP net incomequarter
$71.0 million
Non-GAAP net income for the second quarter of 2025 was $71.0 million, or $2.61 per share, on a diluted basis, compared to $88.3 million, or $3.11 per share, on a diluted basis, during the same period in 2024.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in revenues in 2024.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Operating marginquarter
$652M
" REVENUE GROSS MARGIN OPERATING MARGIN NET CASH FROM OPERATIONS $652M 53.0% 11.8% $117M 2.1% YoY 1.0% YoY CN* -260bps YoY -410bps YoY +$19M YoY 3 Q2 2025 GAAP Financial Results * Percentage revenue change in currency neutral (CN) amounts are calculated by translating prior period revenue in each local currency using the current period s monthly average foreign exchange rates for that currency and comparing that to current period revenue.
SEC original ↗Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025
AI analysis
Q2 2025 · reported Jul 31, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $ 651.6 | — | — |
| Gross margin | 53.0 % | — | — |
| Net income | $317.8 million | — | — |
| Non-GAAP net income | $71.0 million | — | — |
| Operating margin | $652M | — | — |
Guidance · company-stated
“growth of approximately 0 to 1.0 percent”
“is now estimated to be approximately 12.0 to 13.0 percent”
Guidance stated in the release's Business Outlook table for the full year 2025; no direction stated — figures as stated in the table.
Margin
Capital allocation
Americas EMEA 36% APAC 20% Geographic Revenue Mix $389M 8 Balance Sheet Highlights (In $ millions) June 30, 2025 December 31, 2024 Cash & Short-Term Investments $1,374* $1,665 Long-Term Debt $1,201 $1,200 Inventories, net $799 $760 Investment in Sartorius AG $5,156 $4,469 * Cash balance change due to share repurchases, and the completion of Stilla Technologies acquisition on June 30, 2025.
Event summary
Bio-Rad Reports Second -Quarter 2025 Financial Results
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
revenue: “revenue growth of approximately 0 to 1.0 percent”
operating margin: “operating margin is now estimated to be approximately 12.0 to 13.0 percent”
revenue (“the full year 2025”)
“revenue growth of approximately 0 to 1.0 percent”
operating margin (“the full year 2025”)
“operating margin is now estimated to be approximately 12.0 to 13.0 percent”
Guidance stated in the release's Business Outlook table for the full year 2025; no direction stated — figures as stated in the table.
Capital allocation
Americas EMEA 36% APAC 20% Geographic Revenue Mix $389M 8 Balance Sheet Highlights (In $ millions) June 30, 2025 December 31, 2024 Cash & Short-Term Investments $1,374* $1,665 Long-Term Debt $1,201 $1,200 Inventories, net $799 $760 Investment in Sartorius AG $5,156 $4,469 * Cash balance change due to share repurchases, and the completion of Stilla Technologies acquisition on June 30, 2025.
SEC original ↗Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025
Free Cash Flow: Free cash flow is a non-GAAP measure and is defined as cash flow from operations minus net capital expenditures.
SEC original ↗Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025
government sponsored agencies securities 67.9 67.9 Money market funds 103.0 103.0 Total cash equivalents (a) 103.0 101.8 204.8 Restricted investments (b) 1.0 1.0 Equity securities (c) 5,389.4 5,389.4 Loan under the fair value option (d) 369.9 369.9 Available-for-sale investments: Corporate debt securities 475.7 475.7 U.
SEC original ↗Bio-Rad Laboratories, Inc. — 10-Q Quarterly report10-QAug 4, 2026
government sponsored agencies securities 59.9 59.9 Money market funds 209.7 209.7 Total cash equivalents (a) 209.7 100.9 310.6 Restricted investments (b) 1.1 1.1 Equity securities (c) 5,740.5 5,740.5 Loan under the fair value option (d) 373.4 373.4 Available-for-sale investments: Corporate debt securities 451.9 451.9 U.
SEC original ↗Bio-Rad Laboratories, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Level 2 Fair Value Measurements To estimate the fair value of Level 2 debt securities as of June 30, 2026 and December 31, 2025, pricing is obtained from third party pricing services as the primary pricing source.
SEC original ↗Bio-Rad Laboratories, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Our evaluation of credit losses for available-for-sale investments included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency.
SEC original ↗Bio-Rad Laboratories, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Strategy & priorities
2 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management s goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters.
SEC original ↗Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025
The amendments are intended to better reflect those strategies in financial reporting by enabling entities to achieve and maintain hedge accounting for highly effective economic hedges of forecasted transactions.
SEC original ↗Bio-Rad Laboratories, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Risks & headwinds
Significant litigation charges or benefits and legal costs we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
For further information regarding the Company's risks and uncertainties, please refer to the Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations in the Company's public reports filed with the Securities and Exchange Commission (the SEC ), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC.
SEC original ↗Bio-Rad Laboratories, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties.
SEC original ↗Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025
Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations.
SEC original ↗Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025
Legal Proceedings 37 Item 1A.
SEC original ↗Bio-Rad Laboratories, Inc. — 10-Q Quarterly report10-QAug 4, 2026
Earnings deck slides
0 decks with slide viewBio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Bio-Rad Laboratories, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q2 2026
- 10-QBIO
- 8-KBIO
- Q1 2026
- 10-QBIO
- 8-KBIO
Apr 30, 2026
- 8-KBIO
Apr 24, 2026
- Q4 2025
- 8-KBIO
Feb 19, 2026
- 10-KBIO
Feb 13, 2026
- 8-KBIO
Feb 12, 2026
- Q3 2025
- 10-QBIO
- 8-KBIO
Oct 29, 2025
- Q2 2025
- 8-KBIO
Sep 30, 2025
- 8-KBIO
Aug 26, 2025
- 10-QBIO
- 8-KBIO
Jul 31, 2025
- 8-KBIO
Jul 28, 2025
- Q1 2025
- 8-KBIO
Jun 30, 2025
- 10-QBIO
- 8-KBIO
- 8-KBIO
Apr 25, 2025
- Q4 2024
- 8-KBIO
Feb 21, 2025
- 10-KBIO
Feb 14, 2025
- 8-KBIO
Feb 13, 2025
- EX-99BIO
- Q3 2024
- 10-QBIO
- 8-KBIO
Oct 30, 2024
- Q2 2024
- 8-KBIO
- 8-KBIO
Aug 20, 2024
- 10-QBIO
- 8-KBIO
- Q1 2024
- 10-QBIO
- 8-KBIO
Earnings releases
12 documentsPresentations
3 documents
Transcripts
0 documentsNo transcripts for Bio-Rad Laboratories, Inc. are held in this edition of the library.
Mentioned by
7 companiesOther tracked companies whose held documents mention Bio-Rad Laboratories, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“0.81 $ 0.57 Weighted average… …stockholders' equity $ 2,550,601 $ 2,557,868 BIO-TECHNE CORPORATION CONDENSED CONSOLIDATED CASH FLOWS (In thousands) (Unaudited) Nine Months Ended March 31, 2026 … …in”
“shares used in the computation of earnings per share as their effect was anti-dilutive. 5 Bio-Rad Laboratories, Inc. Condensed Consolidated Balance Sheets… …academic research funding affecting our end markets. While we delivered modest revenue growth”
“1.16 $ 0.46 Weighted average… …stockholders' equity $ 2,586,726 $ 2,557,868 BIO-TECHNE CORPORATION CONDENSED CONSOLIDATED CASH FLOWS (In thousands) (Unaudited) Year Ended June 30, 2026 2025 … …in”
“shares used in the computation of earnings per share as their effect was anti-dilutive. 4 BIO-RAD LABORATORIES, INC. Condensed Consolidated Balance Sheets… …(millions) $ 81.1 $ 88.6 Net income (millions) $ 70.2 $ 71.0 Income per diluted share $ 2.62 ”
“shares used in the computation of earnings per share as their effect was anti-dilutive. 4 Bio-Rad Laboratories, Inc. Condensed Consolidated Balance Sheets… …Ended September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 Reconciliat”
“shares used in the computation of earnings per share as their effect was anti-dilutive. 4 BIO-RAD LABORATORIES, INC. Condensed Consolidated Balance Sheets… …1.1% year-over-year. Against this backdrop, we generated strong operating cash flow, $78 mill”
“tements. However,… …consolidated financial statements. F- 3 BELITE BIO INC CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands of US Dollars) (Unaudited) Nine Months Ended September 30,… …including ”
See also the earnings calendar for every tracked company’s next earnings date.